Comments
Lupin on Friday said it has received approval from the US health regulator to market Duloxetine Hydrochloride capsules, used to treat major depressive disorder, in the American market.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for its Duloxetine Hydrochloride Delayed-release (HCl DR) capsules in strengths of 20 mg, 30 mg and 60 mg, Lupin said in a statement. The capsules are the generic equivalent of Eli Lily’s Cymbalta Delayed-release capsules, it added.
According to IMS Health data, Cymbalta HCl DR capsules had annual US sales of nearly $3.5 billion for 12 months to September, it said.
Duloxetine HCl DR capsules are indicated for the treatment of various ailments including major depressive disorder and generalised anxiety disorder (GAD).
Shares of Lupin closed at Rs 441.10 on the BSE, down 0.62 per cent from its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.